Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

NCT05145062 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Blood and Lymphatic Diseases

Interventions

DRUG: BIVV003
DRUG: ST-400

Sponsor

Sangamo Therapeutics